FDG-avid sclerotic bone metastases in breast cancer patients: A PET/CT case series

Annals of Nuclear Medicine

Volumn 26, Issue 1, 2012, Pages 86-91

  Koolen, Bas B ^a   Vegt, Erik ^a   Rutgers, Emiel J Th ^a   Vogel, Wouter V ^a   Stokkel, Marcel P M ^a   Hoefnagel, Cornelis A ^a   Fioole Bruining, Annemarie ^a   Vrancken Peeters, Marie Jeanne T F D ^a   Valdés Olmos, Renato A ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Bone metastases; Breast cancer; PET CT FDG; Sclerotic

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; OSTEOSCLEROSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; BIOLOGICAL TRANSPORT; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84858706115     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0538-3     Document Type: Article

References (21)

1. van der Hoeven JJM, Krak NC, Hoekstra OS, Comans EFI, Boom RPA, van Geldere D, et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol. 2004;22:1253-9. (Pubitemid 41079839)
2. Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, et al. Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol. 2008;19:1249-54. (Pubitemid 351911953)
3. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746-51.
4. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712-20. (Pubitemid 351264383)
5. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508. (Pubitemid 351355215)
6. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-7.
7. Kasem AR, Desai A, Daniell S, Sinha P. Bone scan and liver ultrasound scan in the preoperative staging for primary breast cancer. Breast J. 2006;12:544-8. (Pubitemid 44690843)
8. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol. 2002;128:325-8. (Pubitemid 34569354)
9. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-9. (Pubitemid 28481635)
10. Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med. 2005;19:573-9. (Pubitemid 43161842)
11. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253-8. (Pubitemid 41598715)
12. Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007;25:3440-7. (Pubitemid 47310881)
13. Fogelman I. Osteoblastic bone metastases in breast cancer: is not seeing believing? Eur J Nucl Med Mol Imaging. 2005;32:1250-2. (Pubitemid 41598714)
14. Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426-35.
15. Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166-70.
16. Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med. 2008;33:97-101.
17. Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol. 2010;28:3154-9.
18. Hall FM. Imaging bone metastases in breast cancer. AJR Am J Roentgenol. 2005;185:1082. author reply 1082-3.
19. Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun. 2001;22:875-9. (Pubitemid 32681625)
20. Israel O, Goldberg A, Nachtigal A, Militianu D, Bar-Shalom R, Keidar Z, et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging. 2006;33:1280-4. (Pubitemid 44630782)
21. Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J. 2010;16:617-24.